Updates are available Correction dated 2022-05-24

Article History

Received: 22 November 2021

Accepted: 9 March 2022

First Online: 29 March 2022

Change Date: 24 May 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s13046-022-02398-y

Declarations

:

: All procedures in mice adhered to the “Animal Research: Reporting of In Vivo Experiments” (ARRIVE) standards and were approved by the Ethical Commission of the Candiolo Cancer Institute (Candiolo, Torino, Italy), and by the Italian Ministry of Health. All procedures in monkeys and ethical revision were performed according to the current Italian legislation (Legislative Decree March 4th, 2014 n. 26) enforcing the 2010/63/EU Directive on the protection of animals used for biomedical research. All patients provided written informed consent; samples were collected and the study was conducted under the approval of the review boards of the Candiolo Cancer Institute. The study was done in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonization, and Good Clinical Practice guidelines, and GDPR (General Data Protection Regulation).

: All authors who contributed to the study agree to publish it.

: PMC, JMH, and EV are co-founders of Metis Precision Medicine B-Corp (Torino, Italy). PMC, CB, and EV are authors of the patent application N. PCT/EP2019/077116 “Novel therapeutic agent for the treatment of a tumor and/or metastasis”. The other authors declare no potential conflict of interest.